Literature DB >> 29779158

Diffusion-weighted magnetic resonance enterography for prediction of response to tumor necrosis factor inhibitors in stricturing Crohn's disease.

Marianne M Amitai1,2, Eyal Klang1,2, Asaf Levartovsky2,3, Noa Rozendorn1,2, Shelly Soffer4,5, Gadeer Ali Taha2,3, Bella Ungar2,6, Tomer Greener2,6, Shomron Ben-Horin2,6, Rami Eliakim2,6, Uri Kopylov2,6.   

Abstract

BACKGROUND AND AIMS: Distinguishing between fibrotic and inflammatory strictures in Crohn's disease (CD) is still challenging. The capacity of diffusion-weighted (DWI) magnetic resonance (MRE) to identify intestinal fibrosis was recently demonstrated; however, the therapeutic implications of this association have never been evaluated. The aim of the current study was to identify imaging features, including DWI, which can predict response to anti-inflammatory treatment in patients with stricturing CD.
METHODS: Consecutive CD patients with intestinal strictures that initiated treatment with anti-tumor necrosis alpha (anti-TNF) between June 2012 and April 2017 with MRE adjacent to treatment onset were retrospectively collected. The primary outcome was treatment failure, defined as drug discontinuation, CD-related surgery, or endoscopic dilatation of the stricture. Clinical, demographic, and imaging data were compared between patients who did and did not develop treatment failure within 12 months of anti-TNF treatment initiation.
RESULTS: A total of 21 patients were included in the study; 9/21 (42.8%) developed treatment failure. None of the clinical/demographic parameters were associated with the risk of treatment failure. Among imaging parameters, only ADC value (< 1 × 10-3 mm2/s) was significantly associated with the risk of treatment failure (AUC = 0.81, 66% vs. 0%, p = 0.015).
CONCLUSIONS: Our results suggest that ADC value on DWI MRE may predict the risk of treatment failure in stricturing CD. If replicated in larger studies, these results may guide therapeutic decisions and suggest avoiding anti-TNF treatment.

Entities:  

Keywords:  Crohn’s disease; Diffusion magnetic resonance imaging; Fibrosis; Magnetic resonance imaging; Tumor necrosis factor

Mesh:

Substances:

Year:  2018        PMID: 29779158     DOI: 10.1007/s00261-018-1626-9

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  3 in total

1.  Systematic review: medical therapy for fibrostenosing Crohn's disease.

Authors:  Cathy Lu; Brandon Baraty; Helen Lee Robertson; Alexis Filyk; Hua Shen; Tak Fung; Kerri Novak; Christopher Ma; Remo Panaccione; Jean-Paul Achkar; Sara El Ouali; David Bruining; Vipul Jairath; Brian Feagan; Florian Rieder
Journal:  Aliment Pharmacol Ther       Date:  2020-05-13       Impact factor: 8.171

2.  Real world analysis on the efficacy and safety of anti-tumor necrosis factor therapy in patients with stricturing Crohn's disease.

Authors:  Sudheer K Vuyyuru; Bhaskar Kante; Peeyush Kumar; Pabitra Sahu; Saurabh Kedia; Mukesh Kumar Ranjan; Raju Sharma; Rajesh Panwar; Govind Makharia; Vineet Ahuja
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

Review 3.  Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease.

Authors:  Michele Carvello; Silvio Danese; Antonino Spinelli
Journal:  Clin Colon Rectal Surg       Date:  2022-01-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.